Mainz Biomed N.V., a molecular genetics diagnostic company, is proud to support Colorectal Cancer Awareness Month in March. The company recognizes the importance of early detection and proactive screening in improving survival rates for colorectal cancer (CRC) patients.
Globally, CRC is the second leading cause of cancer-related deaths, with over 930,000 fatalities annually. In the US, approximately 150,000 people are diagnosed with CRC each year, while in Germany, around 22,836 individuals succumb to the disease every year.
Mainz Biomed is committed to combating CRC by advancing diagnostic solutions that focus on early intervention rather than late-stage detection. The company’s next-generation product aims to enable early detection of pre-cancerous adenomas, improving prevention strategies. Its pooled analysis of the ColoFuture and eAArly DETECT studies demonstrated a groundbreaking advanced adenoma detection sensitivity of 82% and specificity of 97%.
Mainz Biomed already enhances the CRC screening landscape by expanding collaborations with laboratories, including its recent partnership in Switzerland. The company also offers at-home testing solutions through its laboratory partner European Oncology Lab, making high-quality DNA-based screening more accessible.
As Colorectal Cancer Awareness Month serves as a crucial reminder that early detection saves lives, Mainz Biomed is committed to driving awareness, expanding access to cutting-edge screening solutions, and empowering individuals to take proactive steps in their health.
Source: https://finance.yahoo.com/news/colorectal-cancer-awareness-month-mainz-130100444.html